New York-based Icahn School of Medicine at Mount Sinai and HTG Molecular Diagnostics announced Nov. 17 they have entered into a new research collaboration as part of HTG’s Transcriptome Panel Early Adopter Program.
Launched in August, HTG’s Transcriptome Panel is designed to measure approximately 20,000 mRNA targets using EdgeSeq technology.
"I believe the ability to capture [approximately] 20,000 genes from a single tissue section with the HTG Transcriptome Panel will be a game-changer," said Amir Horowitz, PhD, assistant professor of oncological sciences at Icahn Mount Sinai.
Through the collaboration, HTG will provide in-kind laboratory services in connection with three separate clinical study cohorts focused on bladder cancer from Icahn Mount Sinai.